David Roman
Stock Analyst at Goldman Sachs
(1.03)
# 1713
Out of 5,240 analysts
22
Total ratings
50.00%
Success rate
12.87%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Edwards Lifesciences | Maintains: Strong Buy | 81 90 | 71.86 | 25.24% | 3 | Dec 5, 2024 | |
HealthEquity | Initiates Coverage On: Neutral | 108 | 101.93 | 5.96% | 1 | Nov 15, 2024 | |
Teladoc Health | Initiates Coverage On: Buy | 14 | 9.43 | 48.46% | 1 | Nov 15, 2024 | |
Doximity | Initiates Coverage On: Neutral | 58 | 51.88 | 11.8% | 1 | Nov 15, 2024 | |
LivaNova | Initiates Coverage On: Buy | 65 | 48.65 | 33.61% | 1 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 78 | 98.76 | -21.02% | 1 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 46 | 36.65 | 25.51% | 1 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 48 54 | 71.68 | -24.67% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 36 40 | 30.73 | 30.17% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 90 | 97.07 | -7.28% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 372 | 367.45 | 1.24% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 500 | 569.99 | -12.28% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 121 | 112.21 | 7.83% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 274 | 237.41 | 15.41% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 129 | 104.73 | 23.17% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sell | 83 | 85.65 | -3.09% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 87 | 86.07 | 1.08% | 1 | May 30, 2024 |